Lumos Pharma, Inc. – NASDAQ:LUMO

Add to watchlist

Market open

Closed in about 1 hour

+163.03%

month

+163.03%

quarter

+48.63%

year

Market Cap	37.53M
Enterprise value	N/A

P/E	-0.93
EV/Sales	-18.20
EV/EBITDA	0.91
Price/Sales	18.41
Price/Book	0.47
PEG ratio	0.56
EPS	-4.59

Revenue	1.52M
EBITDA	-39.42M
Income	-37.12M
Revenue Q/Q	-76.12%
Revenue Y/Y	-27.48%

Profit margin	-2039.53%
Oper. margin	-2103.74%
Gross margin	0%
EBIT margin	-2103.74%
EBITDA margin	-2584.98%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Lumos Pharma, Inc. (NASDAQ:LUMO): Profit margin
Jun 2023	527K	-8.93M	-1694.69%
Sep 2023	7K	-8.3M	-118571.43%
Dec 2023	826K	-9.45M	-1144.92%
Mar 2024	165K	-10.44M	-6327.88%

Lumos Pharma Financials Estimate

Q Y

Lumos Pharma, Inc. (NASDAQ:LUMO): Analyst Estimates
Mar 2024	165K	-10.44M	-6327.88%
Sep 2025	1.17M	-7.29M	-619.95%
Oct 2025	223.38K	-3.16M	-1415.01%
Dec 2025	19.57M	-2.99M	-15.32%

Analysts Price target
Financials & Ratios estimates

Lumos Pharma, Inc. (NASDAQ:LUMO): Debt to assets
Jun 2023	56373000	12.71M	22.55%
Sep 2023	47751000	12.25M	25.67%
Dec 2023	40638000	13.33M	32.81%
Mar 2024	28078000	10.63M	37.89%

Lumos Pharma, Inc. (NASDAQ:LUMO): Cash Flow
Jun 2023	-6.68M	1.08M	-574K
Sep 2023	-7.82M	5.95M	-435K
Dec 2023	-7.39M	6.17M	742K
Mar 2024	-12.89M	1M	-5K

Lumos Pharma alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Lumos Pharma, Inc. (NASDAQ:LUMO): Employee count
Aug 2023	33
Sep 2023	32
Oct 2023	32
Nov 2023	32
Dec 2023	32
Jan 2024	32
Feb 2024	32
Mar 2024	33
Apr 2024	33
May 2024	33
Jun 2024	33
Jul 2024	33

Lumos Pharma
Hedge Funds Holdings Q2 2022

28.41% -1.35%

of LUMO is owned by hedge funds

33 +0

hedge funds hold LUMO stock

2.37M -105.51K

shares is hold by hedge funds

LUMO hedge funds holdings changes

Lumos Pharma, Inc. (NASDAQ:LUMO): Insider trades (number of shares)
Period	Buy	Sel
Sep 2022	4469	0
Nov 2022	4000	0
Feb 2023	0	439
Apr 2023	0	2214
Aug 2023	0	3407

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Aug 2023	MCKEW JOHN C. officer: Chief Sc..	Common Stock	3,407	$3.21	$10,919
Sale	4 Apr 2023	MCKEW JOHN C. officer: Chief Sc..	Common Stock	2,214	$3.27	$7,240
Sale	2 Feb 2023	MCKEW JOHN C. officer: Chief Sc..	Common Stock	439	$3.53	$1,550
Purchase	16 Nov 2022	MCCRACKEN JOSEPH S director director	Common Stock	4,000	$5.03	$20,120
Purchase	23 Sep 2022	HAWKINS RICHARD J director, officer..	Common Stock	208	$8.8	$1,830
Purchase	21 Sep 2022	HAWKINS RICHARD J director, officer..	Common Stock	2,214	$8.84	$19,572
Purchase	20 Sep 2022	HAWKINS RICHARD J director, officer..	Common Stock	1,506	$8.75	$13,178
Purchase	19 Sep 2022	HAWKINS RICHARD J director, officer..	Common Stock	541	$8.65	$4,680
Purchase	25 Aug 2022	MCCRACKEN JOSEPH S director director	Common Stock	3,170	$8.6	$27,262
Purchase	25 Aug 2022	RAFFIN THOMAS A. director director	Common Stock	1,150	$8.46	$9,729

Status	Patent	Filling date	Issue date
Application	Application DETECTING AND TREATING GROWTH HORMONE DEFICIENCY Filling date: 24 Jan 2022 Issue date: 12 May 2022	24 Jan 2022	12 May 2022
Application	Application DETECTING AND TREATING GROWTH HORMONE DEFICIENCY Filling date: 21 Dec 2020 Issue date: 14 Oct 2021	21 Dec 2020	14 Oct 2021
Application	Application COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS Filling date: 14 Feb 2019 Issue date: 4 Mar 2021	14 Feb 2019	4 Mar 2021
Grant	Grant Utility: Detecting and treating growth hormone deficiency Filling date: 20 Sep 2018 Issue date: 26 Jan 2021	20 Sep 2018	26 Jan 2021
Grant	Grant Utility: Synthesis of cyclocreatine and analogs thereof Filling date: 1 Sep 2015 Issue date: 3 Dec 2019	1 Sep 2015	3 Dec 2019
Grant	Grant Utility: Synthesis of cyclocreatine and analogs thereof Filling date: 21 Aug 2018 Issue date: 13 Aug 2019	21 Aug 2018	13 Aug 2019

Lumos Pharma
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 15 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 7 Mar 2024	Q4 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 3 May 2023	Q1 2023 Earnings Call Transcript

LUMO earnings call transcripts

Lumos Pharma
Executives

Insider	Age	Compensation
Mr. Richard J. Hawkins (1949) Chief Executive Officer & Chairman	76	$1,270,000
Dr. John C. McKew Ph.D. (1964) Chief Scientific Officer & Pres	61	$747,990
Mr. Carl W. Langren (1955) Consultant	70	$717,990
Mr. Bradley J. Powers J.D. (1979) Chief Compliance Officer & Gen. Counsel	46	$677,080

Lumos Pharma
Latest News

Thursday, 12 December 2024
08:47	Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma	globenewswire.com
Wednesday, 6 November 2024
14:38	SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO	globenewswire.com
Wednesday, 23 October 2024
15:51	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.	prnewswire.com
15:31	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders	prnewswire.com
10:28	LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders	businesswire.com
Wednesday, 25 September 2024
16:05	Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024	globenewswire.com
Thursday, 15 August 2024
09:00	Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Thursday, 1 August 2024
21:30	Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript	seekingalpha.com
16:05	Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update	globenewswire.com
Tuesday, 23 July 2024
16:05	Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024	globenewswire.com
Monday, 20 May 2024
16:05	Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024	globenewswire.com
Wednesday, 15 May 2024
15:10	Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 14 May 2024
16:15	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results	globenewswire.com
Thursday, 9 May 2024
14:51	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024	GlobeNewsWire
Monday, 26 February 2024
09:00	Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	GlobeNewsWire
Tuesday, 7 November 2023
21:47	Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 7 September 2023
16:34	Lumos Pharma Announces Participation in Investor Conferences in September	GlobeNewsWire
Wednesday, 9 August 2023
22:27	Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 26 July 2023
09:00	Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023	GlobeNewsWire
Wednesday, 3 May 2023
19:02	Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 19 April 2023
09:00	Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023	GlobeNewsWire
Wednesday, 1 March 2023
19:34	Lumos Pharma (LUMO) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 15 February 2023
16:05	Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023	GlobeNewsWire
Monday, 14 November 2022
09:02	Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 9 August 2022
20:36	Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
19:33	Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 16 May 2022
16:05	Lumos Pharma to Participate in Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 10 May 2022
22:03	Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 10 March 2022
22:03	Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 23 February 2022
09:00	Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Lumos Pharma's next earnings date?

Unfortunately, Lumos Pharma's (LUMO) next earnings date is currently unknown.
Does Lumos Pharma pay dividends?

No, Lumos Pharma does not pay dividends.
How much money does Lumos Pharma make?

Lumos Pharma has a market capitalization of 37.53M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.67% to 2.05M US dollars.
What is Lumos Pharma's stock symbol?

Lumos Pharma, Inc. is traded on the NASDAQ under the ticker symbol "LUMO".
What is Lumos Pharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Lumos Pharma?

Shares of Lumos Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Lumos Pharma's key executives?
Lumos Pharma's management team includes the following people:
- Mr. Richard J. Hawkins Chief Executive Officer & Chairman(age: 76, pay: $1,270,000)
- Dr. John C. McKew Ph.D. Chief Scientific Officer & Pres(age: 61, pay: $747,990)
- Mr. Carl W. Langren Consultant(age: 70, pay: $717,990)
- Mr. Bradley J. Powers J.D. Chief Compliance Officer & Gen. Counsel(age: 46, pay: $677,080)
How many employees does Lumos Pharma have?

As Jul 2024, Lumos Pharma employs 33 workers.
When Lumos Pharma went public?

Lumos Pharma, Inc. is publicly traded company for more then 13 years since IPO on 11 Nov 2011.
What is Lumos Pharma's official website?

The official website for Lumos Pharma is lumos-pharma.com.
Where are Lumos Pharma's headquarters?

Lumos Pharma is headquartered at 4200 Marathon Boulevard, Austin, TX.
How can i contact Lumos Pharma?

Lumos Pharma's mailing address is 4200 Marathon Boulevard, Austin, TX and company can be reached via phone at +51 22152630.

Lumos Pharma, Inc.

lumos-pharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

+51 22152630

4200 Marathon Boulevard
Austin, TX 78756

CIK: 0001126234
ISIN: US55028X1090
CUSIP: 55028X109